RT Journal Article
SR Electronic
T1 Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 98
OP 103
DO 10.3949/ccjm.88a.19133
VO 88
IS 2
A1 Haeshik S. Gorr
A1 Lucy Yun Lu
A1 Eric Hung
YR 2021
UL http://www.ccjm.org/content/88/2/98.abstract
AB The 2019 guideline from the Anticoagulation Forum provides clear instructions on how to use 2 agents for reversing the effects of direct oral anticoagulants (DOACs): idarucizumab for dabigatran-associated bleeding and andexanet alfa for bleeding associated with rivaroxaban and apixaban. The guideline also discusses off-label use of andexanet alfa for bleeding associated with edoxaban and betrixaban and the use of hemostatic agents such as activated prothrombin complex concentrate and 4-factor prothrombin complex concentrate. Lastly, it offers approaches for building and managing stewardship programs at the health system level.